| 王 心,胡伟国,宋启斌.乳腺癌激素受体表达对新辅助化疗后病理完全缓解的影响[J].肿瘤学杂志,2022,28(5):360-363. |
| 乳腺癌激素受体表达对新辅助化疗后病理完全缓解的影响 |
| Effect of Hormone Receptor Expression on Pathological Complete Response in Breast Cancer Patients After Neoadjuvant Chemotherapy |
| 投稿时间：2021-12-28 |
| DOI：10.11735/j.issn.1671-170X.2022.05.B004 |
|
 |
| 中文关键词: 乳腺癌 激素受体 人表皮生长因子受体2 新辅助化疗 病理完全缓解 |
| 英文关键词:breast cancer hormone receptor human epidermal growth factor receptor 2 neoadjuvant chemotherapy pathological complete response |
| 基金项目: |
|
| 摘要点击次数: 864 |
| 全文下载次数: 300 |
| 中文摘要: |
| 摘 要：［目的］ 探讨乳腺癌激素受体表达对新辅助化疗后病理完全缓解（pathological complete response，pCR）的影响。［方法］ 回顾性分析2019年11月至2021年10月于武汉大学人民医院首诊为乳腺癌行新辅助化疗并手术108例患者的临床病理资料。依据激素受体（hormone receptor，HR）和人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）表达将患者进行分组，单因素分析采用χ2检验或Fisher精确概率法，两两比较采用Bonferroni校正。多因素分析采用Logistic回归。［结果］ 多因素分析显示雌激素受体（estrogen receptor，ER）及HER2为新辅助化疗后pCR的独立预测因子，ER阴性（OR=13.134，P<0.001）及HER2阳性（OR=0.200，P=0.003）的患者pCR率更高，HR+/HER2-组pCR率最低（2.4%）。亚组分析pCR率观察到统计学差异，差异存在于HR+/HER2-组与其他三组［Bonfeffoni校正，P均<0.008 3(0.05/6)］。［结论］ 不同激素受体表达的乳腺癌患者对新辅助化疗的反应不同。ER阴性、HER2阳性的乳腺癌患者新辅助化疗的效果更好，更易达到pCR。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the effect of hormone receptor expression on pathological complete response(pCR) in breast cancer patient after neoadjuvant chemotherapy. ［Methods］ The clinicopathological data of 108 breast cancer patients admitted in Renmin Hospital of Wuhan University from November 2019 to October 2021 were retrospectively analyzed. The patients were divided into four subgroups according to the expression of hormone receptor(HR) and human epidermal growth factor receptor 2(HER2). Chi-square test or Fisher’s exact test for univariate analysis and Logistic regression analysis for multivariate analysis was used. The Bonferroni correction was used for pairwise comparisons. ［Results］ Multivariate analysis showed that estrogen receptor(ER) and HER2 were independent predictors of pCR after neoadjuvant chemotherapy. ER negative(OR=13.134, P<0.001) and HER2 positive patients(OR=0.200, P=0.003) had higher pCR rate. Compared to other 3 subgroups, HR+/HER2- group had the lowest pCR rate(2.4%)［Bonfeffoni correction P all <0.008 3(0.05/6)］. ［Conclusion］ Breast cancer patients with different hormone receptor expression have different responses to neoadjuvant chemotherapy. Breast cancer patients with ER negative and HER2 positive have better clinical effects when receiving neoadjuvant chemotherapy, and they are more likely to achieve pCR. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|